Aroa Biosurgery Limited

ASX:ARX Stock Report

Market Cap: AU$232.8m

Aroa Biosurgery Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Brian Ward

Chief executive officer

NZ$1.1m

Total compensation

CEO salary percentage54.1%
CEO tenure17.3yrs
CEO ownership9.6%
Management average tenure3.7yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 04
Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%

The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts

Nov 27
The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts

We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn

Nov 13
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn

Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

CEO Compensation Analysis

How has Brian Ward's remuneration changed compared to Aroa Biosurgery's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-NZ$8m

Jun 30 2024n/an/a

-NZ$9m

Mar 31 2024NZ$1mNZ$583k

-NZ$11m

Dec 31 2023n/an/a

-NZ$9m

Sep 30 2023n/an/a

-NZ$8m

Jun 30 2023n/an/a

-NZ$4m

Mar 31 2023NZ$1mNZ$552k

-NZ$396k

Dec 31 2022n/an/a

-NZ$1m

Sep 30 2022n/an/a

-NZ$2m

Jun 30 2022n/an/a

-NZ$5m

Mar 31 2022NZ$1mNZ$542k

-NZ$8m

Dec 31 2021n/an/a

-NZ$10m

Sep 30 2021n/an/a

-NZ$11m

Jun 30 2021n/an/a

-NZ$15m

Mar 31 2021NZ$2mNZ$483k

-NZ$19m

Compensation vs Market: Brian's total compensation ($USD610.60K) is above average for companies of similar size in the Australian market ($USD292.84K).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Ward

17.3yrs

Tenure

NZ$1,078,619

Compensation

Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. He has founded Aroa Biosur...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Ward
Founderno dataNZ$1.08m9.6%
A$ 22.4m
James Agnew
CFO & Joint Company Secretary4.8yrsNZ$627.01kno data
Rod Stanley
Chief Technology Officerless than a yearno datano data
Barnaby May
Chief Scientific Officer3yrsno data0.95%
A$ 2.2m
Neetha Alex-Kumar
General Counselno datano datano data
Frazer Murray
Director of Global Marketing & Strategyno datano datano data
Yasmin Winchester
Vice President of Qualityno datano datano data
Tracy Weimar
Joint Company Secretary4.4yrsno datano data
Adam Young
Vice President of Medical Affairsno datano datano data

3.7yrs

Average Tenure

Experienced Management: ARX's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Ward
Founder17.3yrsNZ$1.08m9.6%
A$ 22.4m
James McLean
Independent Non-Executive Chairperson13.3yrsNZ$212.19k0.82%
A$ 1.9m
John Diddams
Independent Non-Executive Director5.1yrsNZ$159.36k0.35%
A$ 805.0k
John Pinion
Independent Non-Executive Director9.8yrsNZ$187.52k0.14%
A$ 318.9k
Philip McCaw
Non-Executive Director16.8yrsNZ$130.68k5.68%
A$ 13.2m
Catherine Mohr
Independent Non-Executive Director2.1yrsNZ$178.02k0.13%
A$ 294.5k
Darla Hutton
Independent Non-Executive Directorless than a yearNZ$4.73k0.041%
A$ 94.6k

9.8yrs

Average Tenure

58yo

Average Age

Experienced Board: ARX's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 15:34
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aroa Biosurgery Limited is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
Elyse ShapiroBell Potter